Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 51 to 100 of 2425

TitleReference numberPublishedLast updated
Caval valve implantation for tricuspid regurgitationIPG791
Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injuryIPG792
Relugolix for treating hormone-sensitive prostate cancerTA995
Linzagolix for treating moderate to severe symptoms of uterine fibroidsTA996
Diabetic retinopathy: management and monitoringNG242
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal)TA994
Abaloparatide for treating osteoporosis after menopauseTA991
Burosumab for treating X-linked hypophosphataemia in adultsTA993
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attackDG59
AnaphylaxisQS119
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapyTA992
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosisTA988
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia BTA989
Tenecteplase for treating acute ischaemic strokeTA990
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA986
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)TA987
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinomaTA985
Selective internal radiation therapies for treating hepatocellular carcinomaTA688
Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgusIPG789
Tafamidis for treating transthyretin amyloidosis with cardiomyopathyTA984
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinomaTA983
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutationTA979
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)TA980
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA976
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and overTA977
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)TA978
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndromeHST31
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Ranibizumab and pegaptanib for the treatment of age-related macular degenerationTA155
Ranibizumab for treating choroidal neovascularisation associated with pathological myopiaTA298
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusionTA283
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liverIPG786
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetesIPG787
Image-guided percutaneous laser ablation for primary and secondary liver tumoursIPG788
Atogepant for preventing migraineTA973
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underTA975
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancerDG58
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatmentsTA970
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971
COVID-19 rapid guideline: managing COVID-19NG191
Artificial intelligence (AI)-derived software to help clinical decision making in strokeDG57
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTA967
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessmentHTE18
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)TA969

Results per page

  1. 10
  2. 25
  3. 50
  4. All